Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Tan CR, Usmani S, Derkach A, de Meneze Silva Corraes A, Parrondo R, Ailawadhi S, Asoori S, Dave M, Popat R, Morjaria O, Hajek R, Mihalyova J, Htut M, Janakiram M, Visram A, Kastritis E, Dimopoulos MA, Mart?nez-L?pez J, Nagarajan C, Bal S, Costa LJ, Einsele H, Steinbrunn T, Waldschmidt JM, Riedhammer C, Banerjee R, Chng WJ, Tso A, Lin Y, Martin T, Mian H. Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis. Blood Adv. 2026 May 12; 10(9):2937-2946.
-
Specht E, Pakanati L, Wu MJ, Jenkins RW, Effiom DN, Bardeesy N, Bernstein BE, Sade-Feldman M, Lian CG, Boland GM, Torlai Triglia E, Cohen S. Loss of tumor-infiltrating lymphocytes and poor response to immunotherapy in IDH GOF mutant melanoma. JCI Insight. 2026 Jun 08; 11(11).
-
Fernando W, Clucas J, Rizzo A, Singer R, Goode E, Tiu C, Layzell S, Konecnik J, Wilson R, Wicky John S, Jouny S, Guppy N, Boulat V, Mannion J, Goicoechea M, Tan S, Lawson S, Starling C, Elshtein G, Ravindran N, Montgomery AB, Andres-Ejarque R, Allen M, Lumbard S, Wallberg F, Betteridge K, Scrimgeour R, Robertson D, Ward G, Sims M, Smyth T, Samson AL, Murphy JM, Kolarevic Ivankovic D, Arwert EN, Calado DP, Grigoriadis A, Smalley MJ, Melcher A, Haider S, Lawrence T, Roxanis I, Tutt ANJ, Tenev T, Meier P. Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy. Nat Commun. 2026 Mar 06; 17(1).
-
Vyas JM, Feys S, Mansour MK, Wauters J, van de Veerdonk FL. The Changing Paradigm in Infectious Diseases-Host-Directed Medicine: Implications for the Next Generation of ID Physicians. J Infect Dis. 2026 Feb 18; 233(2):230-234.
-
Zhan X, Xiao H, Wang Q, Luo J, Ma L, Zhang X, Tang J, Meng X. Natural killer cell nano-engagers drive ferroptosis-immunomodulation synergy via inhibition of the Interleukin-6-JAK2-STAT3 Axis. J Control Release. 2026 Feb 10; 390:114581.
-
He SQ, Huang Y, Zhao ZY, Wen SQ, Lv SH, Wang L, Bei WX, Xiang YQ, Liu GY. Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study. Br J Cancer. 2026 Feb; 134(4):598-607.
-
Giovannoni F, Strathdee CA, Faust Akl C, Andersen BM, Li Z, Lee HG, Torti MF, Rone JM, Duart-Abadia P, Molgora M, Kong L, Floyd M, Teng J, Gyulakian Y, Grzesik P, Farkaly T, Denslow A, Feau S, Rodriguez-Sanchez I, Jacques J, Colonna M, Kennedy EM, Cheema T, Lerner L, Qu?va C, Quintana FJ. Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy. Nat Cancer. 2025 Dec; 6(12):1994-2010.
-
Murphy KC, DeMarco KD, Zhou L, Peura J, Giwa HK, Lopez-Diaz Y, Ho YJ, Li J, Bai S, Simin K, Zhu LJ, Pitarresi JR, Mercurio AM, Ruscetti M. MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer. Cancer Res. 2025 Nov 14; 85(22):4359-4379.
-
Chowdhury SR, Parikh CN, Kaur AN, DeMarco KD, Giwa HK, Mishra AK, Murphy KC, Zhou L, Ma B, Ye T, Li J, Liu H, Bai S, Johnson C, Simin K, Pitarresi JR, Zhu LJ, Watson EV, Kelliher MA, Green MR, Fitzgerald KA, Ruscetti M. PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors. Proc Natl Acad Sci U S A. 2025 Sep 30; 122(39):e2514948122.
-
Krieg AM. New insights into the role of IFN-a/? and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity. J Immunother Cancer. 2025 Sep 18; 13(9).